Sulfonylurea News and Research

RSS

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Metformin gets top grade for diabetes

A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.

26 Jul 2007

Colesevelam HCl hits diabetes with one-two punch

Patients with type 2 diabetes may soon be able to control their glucose and their cholesterol levels with a single drug, according to a study led by Vivian A.

9 Jul 2007

GSK strongly disagrees with conclusions reached in NEJM article on Avandia

GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.

22 May 2007

Race affects medication adherence

African Americans may be less likely than whites to take their medication for Type 2 diabetes as it is prescribed, a new study suggests.

2 Aug 2006

Latest diabetic medications more costly, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

22 Mar 2006

Chronic use of nitroglycerin for chest pain could lead to mitochondrial damage

Definitive evidence to explain how the drug nitroglycerin relieves chest pain has resulted from a new study by Howard Hughes Medical Institute investigators at Duke University Medical Center. Nitroglycerin relaxes blood vessels to boost blood flow, yet the mechanism by which the drug works has remained a matter of scientific controversy.

16 Aug 2005

Oral medications may control symptoms of Type II diabetes in children just as well as insulin injections

According to the medical records of 26 children diagnosed with the disease, oral medications reduced levels of a compound in the blood called hemoglobin A1C by an average of 2 percentage points.

15 Aug 2005

Takeda Pharmaceuticals submits NDA for a new oral diabetes medication

Takeda Pharmaceuticals North America today announced that the company has submitted a New Drug Application (NDA) for a new oral medication that combines pioglitazone HCl and glimepiride, a sulfonylurea, to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

30 Jun 2005

Chromium picolinate significantly reduces weight gain associated with common antidiabetic medication

...according to a study released today. Researchers at the Pennington Biomedical Research Center (PBRC), who conducted the study, also found that chromium significantly improved blood sugar control and insulin sensitivity.

16 Jun 2005

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes

The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.

12 Jun 2005

Muraglitazar lowers blood glucose and helps dyslipidemia seen in diabetes

A novel compound provides long-term lowering of blood glucose levels and improves plasma lipids (fats) that are often a problem in people with type 2 diabetes -- all in a once-daily pill, according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.

12 Jun 2005

Exubera shows sustained blood glucose control in patients with type 2 diabetes

New data showed that Exubera (inhaled insulin) was effective and well tolerated in controlling blood glucose levels over a two-year period in patients with Type 2 diabetes.

8 Sep 2004

New drug application for exenatide has been accepted for review

Amylin Pharmaceuticals and Eli Lilly today announced that the New Drug Application for exenatide has been accepted for review by the Food and Drug Administration.

2 Sep 2004

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for regulatory approval of exenatide.

1 Jul 2004

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session at the American Diabetes Association's (ADA) 64th Scientific Sessions in Orlando, Florida.

5 Jun 2004

Addition of insulin sensitizer provides lipid benefits for patients with type 2 diabetes

Results of three studies show the oral anti-diabetic agent ACTOS (R) (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline.

30 Apr 2004